3-Amido pyrrolopyrazine JAK kinase inhibitors: development of a JAK3 vs JAK1 selective inhibitor and evaluation in cellular and in vivo models
about
In vivo administration of a JAK3 inhibitor during acute SIV infection leads to significant increases in viral load during chronic infectionAdvances in kinase inhibition: treating rheumatic diseases and beyond.In vivo administration of a JAK3 inhibitor to chronically siv infected rhesus macaques leads to NK cell depletion associated with transient modest increase in viral loads.Novel hinge-binding motifs for Janus kinase 3 inhibitors: a comprehensive structure-activity relationship study on tofacitinib bioisosteres.Pharmacophore and Virtual Screening of JAK3 inhibitors.Selective JAK inhibitors.Oxindole-based SYK and JAK3 dual inhibitors for rheumatoid arthritis: designing, synthesis and biological evaluation.Development of Selective Covalent Janus Kinase 3 Inhibitors.Highly selective Janus kinase 3 inhibitors based on a pyrrolo[2,3-d]pyrimidine scaffold: evaluation of WO2013085802.Molecular dynamics and integrated pharmacophore-based identification of dual [Formula: see text] inhibitors.Dual inhibitors of Janus kinase 2 and 3 (JAK2/3): designing by pharmacophore- and docking-based virtual screening approach.Discovery of a highly selective JAK3 inhibitor for the treatment of rheumatoid arthritis.The role of ligand efficiency metrics in drug discovery.Ligand-based and e-pharmacophore modeling, 3D-QSAR and hierarchical virtual screening to identify dual inhibitors of spleen tyrosine kinase (Syk) and janus kinase 3 (JAK3).
P2860
Q27330386-66F3E331-255D-4EDD-A5DD-20655C107A96Q33930795-391C6A1E-D821-4474-9876-F3C55A0EA2ECQ34907640-4B969538-8A56-4020-95DB-7E75B67023B5Q35228409-F4E0CFD2-A6EF-42C3-90EC-A73490F7AA5FQ37682063-3527A562-A677-4C9F-9D53-B8F99C6520E3Q38261371-AD0C5D8C-DBF4-4B41-BFE1-74F40E9BCC5AQ38655324-B93DFA43-FBD0-4B13-838E-D0912E4CAA83Q38763094-78108A56-E49D-45AC-B37A-273A4A3ED353Q46460981-0E4D941B-A79E-434C-8076-F678164E1AE3Q47401024-C32FE953-2BC6-412B-9450-691A8F488D91Q51759248-5D01C329-67D4-4498-8516-22B68A472EE2Q52626728-0D1B7514-678D-4A98-8895-810CA8B2F26DQ53297758-0D1B628A-34EA-438E-AB4F-B8106F24B1D2Q54172917-3F54E81F-885F-4490-B7BB-1821D1AD1672
P2860
3-Amido pyrrolopyrazine JAK kinase inhibitors: development of a JAK3 vs JAK1 selective inhibitor and evaluation in cellular and in vivo models
description
2013 nî lūn-bûn
@nan
2013 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
3-Amido pyrrolopyrazine JAK ki ...... in cellular and in vivo models
@ast
3-Amido pyrrolopyrazine JAK ki ...... in cellular and in vivo models
@en
3-Amido pyrrolopyrazine JAK ki ...... in cellular and in vivo models
@nl
type
label
3-Amido pyrrolopyrazine JAK ki ...... in cellular and in vivo models
@ast
3-Amido pyrrolopyrazine JAK ki ...... in cellular and in vivo models
@en
3-Amido pyrrolopyrazine JAK ki ...... in cellular and in vivo models
@nl
prefLabel
3-Amido pyrrolopyrazine JAK ki ...... in cellular and in vivo models
@ast
3-Amido pyrrolopyrazine JAK ki ...... in cellular and in vivo models
@en
3-Amido pyrrolopyrazine JAK ki ...... in cellular and in vivo models
@nl
P2093
P356
P1476
3-Amido pyrrolopyrazine JAK ki ...... in cellular and in vivo models
@en
P2093
Alam Jahangir
Alan K Kutach
Andrea Itano
Ann Hoffman
Aruna Railkar
Calvin Yee
Cheng Liao
David Shaw
Dong-Qing Hu
P304
P356
10.1021/JM301646K
P407
P577
2013-01-10T00:00:00Z